VenatoRx Receives $9.4 Million from CARB-X to Develop a New Class of Antibiotic to Combat Multi-Drug Resistant Bacteria
VenatoRx Receives $9.4 Million from CARB-X to Develop a New Class of Antibiotic to Combat Multi-Drug Resistant Bacteria
Comments are closed.